% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Peng:298907,
author = {T. Peng and X. Ma$^*$ and W. Hua and C. Wang$^*$ and Y. Chu
and M. Sun and V. Fermi and S. Hamelmann$^*$ and K.
Lindner$^*$ and C. Shao$^*$ and J. Zaman$^*$ and W. Tian$^*$
and Y. Zhuo$^*$ and Y. Harim$^*$ and N. Stöffler$^*$ and L.
Hammann$^*$ and Q. Xiao$^*$ and X. Jin$^*$ and R. Warta and
C. Lotsch and X. Zhuang and Y. Feng and M. Fu and X. Zhang
and J. Zhang and H. Xu and F. Qiu and L. Xie and Y. Zhang
and W. Zhu and Z. Du and L. Salgueiro$^*$ and M. Schneider
and F. Eichhorn and A. Lefevre and S. Pusch$^*$ and V.
Grinevich and M. Ratliff$^*$ and S. Loges$^*$ and L.
Bunse$^*$ and F. Sahm$^*$ and Y. Xiang and A. Unterberg and
A. von Deimling$^*$ and M. Platten$^*$ and C. Herold-Mende
and Y. Wu and H. Liu$^*$ and Y. Mao},
title = {{I}ndividualized patient tumor organoids faithfully
preserve human brain tumor ecosystems and predict patient
response to therapy.},
journal = {Cell stem cell},
volume = {32},
number = {4},
issn = {1934-5909},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2025-00346},
pages = {652-669.e11},
year = {2025},
note = {DKFZ-ZMBH Alliance / #EA:A240# / HI-TRON / 2025 Apr
3;32(4):652-669.e11},
abstract = {Tumor organoids are important tools for cancer research,
but current models have drawbacks that limit their
applications for predicting response to therapy. Here, we
developed a fast, efficient, and complex culture system
(IPTO, individualized patient tumor organoid) that
accurately recapitulates the cellular and molecular
pathology of human brain tumors. Patient-derived tumor
explants were cultured in induced pluripotent stem cell
(iPSC)-derived cerebral organoids, thus enabling culture of
a wide range of human tumors in the central nervous system
(CNS), including adult, pediatric, and metastatic brain
cancers. Histopathological, genomic, epigenomic, and
single-cell RNA sequencing (scRNA-seq) analyses demonstrated
that the IPTO model recapitulates cellular heterogeneity and
molecular features of original tumors. Crucially, we showed
that the IPTO model predicts patient-specific drug
responses, including resistance mechanisms, in a prospective
patient cohort. Collectively, the IPTO model represents a
major breakthrough in preclinical modeling of human cancers,
which provides a path toward personalized cancer therapy.},
keywords = {brain metastasis (Other) / glioblastoma (Other) / patient
tumor organoid (Other) / predictive patient model (Other) /
temozolomide (Other) / tumor heterogeneity (Other)},
cin = {A240 / B300 / HD01 / D170 / B320 / A420},
ddc = {570},
cid = {I:(DE-He78)A240-20160331 / I:(DE-He78)B300-20160331 /
I:(DE-He78)HD01-20160331 / I:(DE-He78)D170-20160331 /
I:(DE-He78)B320-20160331 / I:(DE-He78)A420-20160331},
pnm = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
pid = {G:(DE-HGF)POF4-311},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:39938519},
doi = {10.1016/j.stem.2025.01.002},
url = {https://inrepo02.dkfz.de/record/298907},
}